|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Celleration, Inc. Closing in on $7 Million Round of Funding
1/15/2013 8:09:36 AM
Wound-healing med-tech firm Celleration Inc. is close to wrapping up a $7 million round of financing as it expands product sales into the U.K. The Eden Prairie-based company makes a device called Mist Therapy, which uses ultrasonic waves to treat stubborn-to-heal wounds such as diabetic foot ulcers. Celleration’s technology emits ultrasonic vibrations and delivers a mist to injured tissue. The mist removes bacteria and stimulates cells, helping wounds heal. The treatment is painless, and it targets wounds in the lower extremities. Celleration raised its recent round of financing from previous investors and high net-worth individuals, said Celleration CEO Mark Wagner. The company’s past investors include Minneapolis-based venture-capital firm SightLine Partners, Cedar Rapids, Iowa-based Aavin Equity Advisors, Minneapolis-based Affinity Capital Management, and Chicago-based Baird Venture Partners. The fund-raising environment for med-tech firms is challenging, partly due to a new excise tax on medical devices that went into effect this year, Wagner said. The company succeeded partly due to its device’s long track record, as Mist has now been used to treated one million patients, he said.
|
|
|
|
|
|
|
|
|
|
|